智通财经APP获悉，开拓药业-B(09939)再涨近5%，截至发稿，涨3.86%，报4.04港元，成交额1171.01万港元。
消息面上，近日，开拓药业在投资平台表示，其自主研发的外用雄激素受体（AR）拮抗剂KX-826，1.0%酊剂治疗男性雄激素性脱发（AGA）的Ⅲ期临床顶线数据，将于2026年3月中下旬正式披露。凭借扎实的临床数据，KX-826成功获得国际化妆品成分INCI命名，成为合规化妆品原料。
公开资料显示，2026年1月，公司与德开医药签订防脱泡沫剂（KX-826衍生产品）国内独家销售协议，接入覆盖全国的成熟销售网络，为药物上市后的快速市场渗透提前布局，进一步拓展了KX-826未来商业化布局空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.